In a report released today, Matthew O’Brien from Piper Sandler maintained a Hold rating on Globus Medical (GMED – Research Report), with a price target of $55.00. The company’s shares closed yesterday at $54.40.
According to TipRanks, O’Brien is a 5-star analyst with an average return of 7.2% and a 52.95% success rate. O’Brien covers the Healthcare sector, focusing on stocks such as Medtronic, Alphatec Holdings, and Atricure.
In addition to Piper Sandler, Globus Medical also received a Hold from Needham’s David Saxon in a report issued today. However, yesterday, Bank of America Securities reiterated a Sell rating on Globus Medical (NYSE: GMED).
See Insiders’ Hot Stocks on TipRanks >>
GMED market cap is currently $7.39B and has a P/E ratio of 34.82.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical (GMED) Company Description:
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
Read More on GMED:
- Globus Medical Reports Preliminary Record Fourth Quarter and Full Year Sales Results
- Globus Medical price target lowered to $83 from $86 at Barclays
- Globus Medical price target raised to $58 from $53 at Truist
- Globus Medical price target raised to $71 from $67 at Canaccord
- Globus Medical price target lowered to $53 from $60 at Morgan Stanley
